Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas

Clinical Trial ID NCT00076102

PubWeight™ 3.68‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00076102

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002 5.06
2 Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Neuro Oncol 2014 1.66
3 Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models. J Clin Invest 2000 1.56
4 Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel Ther 2015 1.33
5 Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone. Int J Immunopharmacol 1998 0.91
6 Advances in paediatric cancer treatment. Transl Pediatr 2014 0.76
Next 100